EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieOpen Access · CC BY-NC-ND 4.0

Amiloride versus furosemide for the treatment of edema in patients with nephrotic syndrome: A pilot study ( AMILOR )

Anja Schork, Elisabeth Vogel, Bernhard N Bohnert iD, Daniel Essigke, Matthias Wörn, Imma Fischer, Nils Heyne, Andreas L Birkenfeld, Ferruh Artunc iD

Acta Physiologica · 2024-08 · 240 (8)

DOI: 10.1111/apha.14183 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Acta Physiologica, 2024-06. Verfasst von Anja Schork und 8 weiteren Autor:innen. Beteiligte Einrichtung: Division of Diabetology, Endocrinology and Nephrology, Department of Internal Medicine IV, University Hospital Tübingen, Tübingen, Germany. Hauptthemen laut MEDLINE: Amiloride, Furosemide, Nephrotic Syndrome, Diuretics. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Medical Faculty of Tübingen University, German Research Foundation, Deutsche Forschungsgemeinschaft.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aim

In rodent models of nephrotic syndrome (NS), edema formation was prevented by blockade of the epithelial sodium channel ENaC with amiloride. However, apart from case reports, there is no evidence favoring ENaC blockade in patients with NS.

Methods

The monocentric randomized controlled AMILOR study investigated the antiedematous effect of amiloride (starting dose 5 mg/day, max. 15 mg/day) in comparison to standard therapy with the loop diuretic furosemide (40 mg/day, max. 120 mg/day) over 16 days. Overhydration (OH) was measured by bioimpedance spectroscopy (BCM, Fresenius). Depending on the OH response, diuretic dose was adjusted on days 2, 5, 8 and 12, and if necessary, hydrochlorothiazide (HCT) was added from d8 (12.5 mg/day, max. 25 mg/day). The primary endpoint was the decrease in OH on d8. The study was terminated prematurely due to insufficient recruitment and a low statistical power due to a low actual effect size.

Results

Median baseline OH was +26.4 (interquartile range 15.5–35.1)% extracellular water (ECW) in the amiloride arm and + 27.9 (24.1–29.4)% ECW in the furosemide arm and decreased by 1.95 (0.80–6.40) and 5.15 (0.90–8.30)% ECW after 8 days, respectively, and by 10.10 (1.30–14.40) and 7.40 (2.80–10.10)% ECW after 16 days, respectively. OH decrease on d8 and d16 was not significantly different between both arms.

Conclusion

The AMILOR study is the first randomized controlled pilot study suggesting a similar antiedematous effect as furosemide. Further studies are required to better define the role of amiloride in NS (EudraCT 2019‐002607‐18).

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AmilorideFurosemideNephrotic SyndromeDiureticsEdemaHumansPilot ProjectsMaleFemaleMiddle AgedAdultEpithelial Sodium Channel BlockersAged

Stichwörter der Autor:innen

amilorideedemaepithelial sodium channelsfurosemidenephrotic syndrome

Substanzen

AmilorideFurosemideDiureticsEpithelial Sodium Channel Blockers

Autor:innen und Institutionen

  • Division of Diabetology, Endocrinology and Nephrology, Department of Internal Medicine IV, University Hospital Tübingen, Tübingen, Germany.
  • Institute of Diabetes Research and Metabolic Diseases (IDM) of the Helmholtz Center Munich at the University of Tübingen, Tübingen, Germany.
  • German Center for Diabetes Research (DZD), Tübingen, Germany.
  • Institute for Clinical Epidemiology and Applied Biometry, University Hospital Tübingen, Tübingen, Germany.

ORCID-Profile: Bernhard N Bohnert, Ferruh Artunc

Förderung

  • Medical Faculty of Tübingen University
  • German Research Foundation
  • Deutsche Forschungsgemeinschaft

Zitieren

APA

Schork, A., Vogel, E., Bohnert, B. N., Essigke, D., Wörn, M., Fischer, I., Heyne, N., Birkenfeld, A. L., & Artunc, F. (2024). Amiloride versus furosemide for the treatment of edema in patients with nephrotic syndrome: A pilot study ( AMILOR ). Acta Physiologica, 240(8). https://doi.org/10.1111/apha.14183

Vancouver

Schork A, Vogel E, Bohnert BN, Essigke D, Wörn M, Fischer I, et al. Amiloride versus furosemide for the treatment of edema in patients with nephrotic syndrome: A pilot study ( AMILOR ). Acta Physiologica. 2024;240(8). doi:10.1111/apha.14183

BibTeX
@article{Schork2024,
  author = {Schork, Anja and Vogel, Elisabeth and Bohnert, Bernhard N and Essigke, Daniel and Wörn, Matthias and Fischer, Imma and Heyne, Nils and Birkenfeld, Andreas L and Artunc, Ferruh},
  title = {Amiloride versus furosemide for the treatment of edema in patients with nephrotic syndrome: A pilot study ( AMILOR )},
  journal = {Acta Physiologica},
  year = {2024},
  volume = {240},
  number = {8},
  doi = {10.1111/apha.14183}
}
Kostenlos starten →